ROR1 and sarcoma: Preclinical studies have also suggested a promising activity of CAR T cells targeting the type I insulin-like growth factor receptor (IGF1R) and the tyrosine–kinase-like orphan receptor 1 (ROR1), which are highly expressed in sarcoma cell lines [178].